Prøve GULL - Gratis
Demand For Specialised Infrastructure, Incubators Continues To Be Moderate To Strong
Bio Spectrum
|February 2017
Utkarsh Palnitkar says only a few biotech parks support industry with ready-to-use lab facilities for R&D, incubation support for start-ups and dedicated land for scaling up activities are operational in India.

Admitting that there is a sustained interest across the biopharma value chain, Utkarsh Palnitkar, Co-Chairman of the Review Committee for Biotech Parks, DBT, Government of India (GoI), Partner and National Head (Infrastructure, Government, Healthcare and Life Sciences Practice), KPMG, states that the demand for specialised infrastructure and incubators continues to be moderate to strong. He tells BioSpectrum that more than 15 biotech parks are operating currently in the country and many upcoming parks are still at an initial stage of conducting basic ground work for their establishment.
What is the current status of BT parks in India and their occupancy level? Which states are doing great, which are ok and which are below average? Some parks believed to have very low level of occupancy. Which are they and what are the reasons for the same?
With the sustained interest across the biopharma value chain, the demand for specialised infrastructure and incubators continues to be moderate to strong. Currently, more than 15 biotech parks are operational in the country and many upcoming parks are still at an initial stage of conducting basic ground work for their establishment.
The Department of Biotechnology (DBT), together with various state governments are playing a major role in setting up biotechnology parks across the country.
The occupancy level in biotech parks depends upon various factors such as the availability of the specialised infrastructure, incubation facilities, enabling ecosystem and state policies, among others. The prevalence of a vibrant ecosystem is essential to the success of the Park. While at many locations elements of the ecosystem exists, they being joined together is at time absent. This is reflected in the mixed level of success in this space.
Denne historien er fra February 2017-utgaven av Bio Spectrum.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA Bio Spectrum

Bio Spectrum
WHO certifies Suriname malaria-free
Suriname became the first country in the Amazon region to receive malaria-free certification from the World Health Organization (WHO).
1 min
August 2025

Bio Spectrum
Torrent Pharma buys controlling stake in JB Pharma from KKR for Rs 25,689 Cr valuation
Ahmedabad-based Torrent Pharmaceuticals and global investment firm KKR have announced that Torrent has entered into definitive agreements to acquire controlling stake in Mumbai-based J. B. Chemicals and Pharmaceuticals (JB Pharma) from KKR at an Equity Valuation of Rs 25,689 crore (on fully diluted basis), followed by a merger of the two entities.
1 min
August 2025
Bio Spectrum
Suraksha Diagnostics injects Rs 22 Cr to establish Eastern India's largest genomics lab
Suraksha Diagnostics, one of the leading diagnostics chains in Eastern India, has launched one of the largest and a state-of-theart genomics lab in Eastern India.
1 min
August 2025
Bio Spectrum
Illumina buys SomaLogic for $425 M to accelerate proteomics business
Illumina, Inc. has entered into a definitive agreement with Standard BioTools under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties.
1 min
August 2025

Bio Spectrum
Kashmik Formulation to expand capacity, eyes Rs 100 Cr revenue in FY26
Kashmik Formulation, a pharmaceutical manufacturing company headquartered in Ahmedabad, has announced significant expansion plans aimed at increasing production capacity, strengthening its presence in international markets, and enhancing operational efficiencies through automation.
1 min
August 2025
Bio Spectrum
WHO highlights risks associated with use of semaglutide medicines
The World Health Organisation (WHO) is alerting healthcare professionals and regulatory authorities to the risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of semaglutide medicinesOzempic, Rybelsus, and Wegovy.
1 min
August 2025

Bio Spectrum
Lamark Biotech secures Rs 6.5 Cr to accelerate development of thermostable insulin
Lamark Biotech, an innovation-led biopharma startup, has raised Rs 6.5 crore in a PreSeries A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Dr Vinayender Tulla, Dr Nita Roy, and Venkataraman KNK, domain experts of IAN's angel investors led the round.
1 min
August 2025

Bio Spectrum
AstraZeneca invests Rs 166 Cr to expand Global Hub in Bengaluru
AstraZeneca, a global, science-led biopharmaceutical company, has announced the expansion of its state-of-the-art Global Hub in Bengaluru, strengthening its presence in India.
1 min
August 2025

Bio Spectrum
Novo Nordisk launches injectable Semaglutide for weight management in India
Novo Nordisk, a leading global healthcare company headquartered in Denmark with over a 100-year legacy of chronic disease care, has announced the launch of Wegovy (injectable Semaglutide) in India.
1 min
August 2025

Bio Spectrum
Can Policy Reforms & Investments Trigger India's MedTech MAKEOVER?
India's MedTech sector has long been import-dependent. The Centre is now working to change this by positioning the country as an export-oriented manufacturing hub. A series of policies and investments have been introduced to support this shift. Have these made an impact? What steps are necessary to strengthen India's position in the global medical technology (MedTech) landscape? Let's find out.
12 mins
August 2025
Translate
Change font size